Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
Kke4rE4Nx0g7UC1h
